Gynecologic Oncology

Nikita Sinha, MD, discusses the potential effects of onvansertib on endometroid endometrial cancer pathogenesis in a preclinical model.

Danielle Krause, MD, discusses preclinical findings from mouse models evaluating GLP-1 agonists with and without progesterone in endometrial cancer.

Paulina J. Haight, MD, discusses the association between the occurrence of toxicities with response to treatment with lenvatinib and pembrolizumab.

Danielle Krause, MD, discusses the effects of GLP-1 receptor agonist therapy in endometrial cancer.

Paulina J Haight, MD, discusses predictors of toxicity and treatment response with lenvatinib and pembrolizumab in patients with gynecologic malignancies.

Ritu Salani, MD, presents an outline of the treatment landscape for ovarian cancer and underscores encouraging data from the DESTINY-PanTumor02 study, showcasing promising results in this treatment setting.

Martin Dietrich, MD, PhD, discusses the role of HER2 ADCs in GI cancers, reviewing key data from DESTINY-Gastric and DESTINY-CRC trials.

Genetic screening and testing have only recently become an integral part of cancer care.

Martin Dietrich, MD, PhD, examines the safety and efficacy of HER2-directed ADCs in NSCLC, emphasizing significant differences in response associated with HER alterations.

Martin Dietrich, MD, PhD, offers a comprehensive review of the efficacy and safety of HER2 ADCs in breast cancer, underscoring their substantial impact on treatment practices in both HER2+ and HER2-low.

The panel closes their discussion by highlighting challenges in the treatment of cervical cancer, emphasizing the need for more focus on clinical trials and therapies, as well as addressing disparities in cancer care, particularly for patients of color.

Updated data from several clinical trials in endometrial and cervical cancer could signal the emergence of multiple effective options coming down the pike.

The FDA has approved pembrolizumab (Keytruda) plus chemoradiation for patients with FIGO 2014 stage III to IVA cervical cancer.

Martin Dietrich, MD, PhD, reflects on the lessons and insights gleaned from HER2 in breast cancer, examining their influence on the development of treatment approaches utilizing HER2-targeted therapies in other solid tumors.

Martin Dietrich, MD, PhD, presents a thorough analysis of HER2 as a pan-tumor biomarker, underscoring its universal importance in the field of oncology.

Drs Monk and Tarantino highlight current research investigating B7-H4–directed antibody-drug conjugates. in multiple solid tumor types.

Eirwen M. Miller, MD, spotlights updated data within the endometrial, cervical, and ovarian cancer spaces following the 2023 ESMO Congress.

Bradley Monk, MD, shares the promising potential of anti-HER2 therapy in cervical cancer and discusses encouraging results from recent trials, emphasizing the importance of testing for HER2 and considering anti-HER2 antibody drug conjugates as a treatment option.

Experts in gynecologic oncology discuss the positive results of TV-301, a confirmatory trial for TV-204, raising the possibility of moving tisotumab vedotin earlier in the treatment of patients with cervical cancer, and the potential to combine it with pembrolizumab.

The FDA has granted priority review to a sBLA seeking to convert the accelerated approval of tisotumab vedotin to full approval in select patients with cervical cancer.

Eirwen M. Miller, MD, highlights data that have impacted the treatment armamentarium for patients with endometrial cancer and mismatch repair–deficient or mismatch repair–proficient disease throughout the course of 2023.

Ignace B. Vergote, MD, PhD, discusses the efficacy of tisotumab vedotin-tftv in patients with recurrent or metastatic cervical cancer, according to data from the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial (NCT04697628).

Debra L. Richardson, MD, FACS, FACOG, discusses the impact of selinexor’s mechanism of action on the agent’s clinical efficacy in patients with TP53 wild-type advanced or recurrent endometrial cancer.

Experts detail the management of ocular toxicity associated with tisotumab vedotin in patients with cervical cancer, emphasizing the need for eye care professionals and a team approach, along with addressing peripheral neuropathy.

Dana M. Chase, MD, FACOG, discusses the antibody-drug conjugate tisotumab vedotin including its mechanism of action, its accelerated approval for patients with recurrent cervical cancer and at least one prior line of therapy, and the management of toxicities such as neuropathy and pneumonitis.